|

Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer

RECRUITINGSponsored by Centre Hospitalier Universitaire de Nīmes
Actively Recruiting
SponsorCentre Hospitalier Universitaire de Nīmes
Started2024-09-26
Est. completion2027-05
Eligibility
Age18 Years+
SexFEMALE
View on ClinicalTrials.gov →

NCT06147960

Summary

Overexpression of inhibitors of apoptosis proteins (IAPs) in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy may have a prognostic role on the local recurrence rate at 24 months.

Eligibility

Age: 18 Years+Sex: FEMALE
Inclusion Criteria:

* Patients treated with the exclusive radio-chemotherapy combination for locally advanced cervical carcinoma (stage Ib-IVb according to FIGO classification).
* Patients aged ≥ 18 years.
* Patients with a minimum of 2 years post-treatment follow-up.
* Patients for whom the initial biopsy specimen (before treatment) is available.
* Patients who have not indicated that they do not wish to participate in the study.
* Patients affiliated to or benefiting from a health insurance scheme.

Exclusion Criteria:

* Patients under court protection, guardianship or curatorship.

Conditions3

ApoptosisCancerCancer of Cervix

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.